Found 16 articles for: "Cutaneous"
The Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MoreCutaneous Collagenous Vasculopathy Treated With Pulsed Dye Laser: A Case Series and Literature Review
December 2024 | Volume 23 | Issue 12 | Case Reports | 1121 | Copyright © December 2024
Cutaneous collagenous vasculopathy (CCV) is an underreported cutaneous microangiopathy that primarily involves the lower extremities. Optimal treatment of CCV has not been well-defined, which may...
Read MoreFunctional and Cutaneous Treatment Outcomes With Intravenous Immunoglobulin for Eosinophilic Fasciitis: A Retrospective Study
April 2024 | Volume 23 | Issue 4 | Editorials | e107 | Copyright © April 2024
Background: Eosinophilic fasciitis (EF) is a rare subtype of deep morphea with an elevated risk of functional impairment. No treatment algorithm has been established for adults w...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreInnate Error Immunities of the Th17 Immune Pathway Associated With Chronic Mucocutaneous Candidiasis: A Systematic Review
December 2023 | Volume 22 | Issue 12 | Original Article | 1197 | Copyright © December 2023
Background: Candida albicans is an opportunistic pathogenic yeast commensal in human mucosa. In individuals with compromised immune systems, it can present as chronic mu...
Read MoreTocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects
December 2023 | Volume 22 | Issue 12 | Editorials | e42 | Copyright © December 2023
Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocil...
Read MoreThe Interventions to Minimize Pain During Photodynamic Therapy With 5-Aminolevulinic Acid for the Treatment of Cutaneous Diseases
November 2023 | Volume 22 | Issue 11 | Original Article | 1082 | Copyright © November 2023
Read MoreCutaneous Sarcoidosis in Skin of Color
July 2023 | Volume 22 | Issue 7 | Features | 695 | Copyright © July 2023
Cutaneous sarcoidosis presents in 25% of all sarcoidosis cases. African American populations, particularly African American women, are more likely to develop the dermatologic manifestations of th...
Read MoreManaging Monkeypox Virus: Characterizing Common Cutaneous Manifestations and Antiviral Efficacy
March 2023 | Volume 22 | Issue 3 | Original Article | 282 | Copyright © March 2023
Background: The Monkeypox virus (MPX) has been detected in multiple non-endemic countries since May 2022. The cutaneous manifestations of MPX can have multiple distinct presentat...
Read MoreThe Effect of an Autologous Protein-Based Topical Serum on Cutaneous Burns
December 2022 | Volume 21 | Issue 12 | Original Article | 1330 | Copyright © December 2022
Background: Burns are skin lesions that can be life-threatening. Platelet-rich plasma (PRP) is growing as an effective alternative for the management of burns. The objective of this s...
Read MoreTreatment and Maintenance of Cutaneous Rosacea in Latino Skin Types With Prescription Medications and Non-Prescription Cleansers and Moisturizers as Adjuncts: A Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1111 | Copyright © October 2022
Background: Rosacea is an inflammatory dermatosis with at least a ten percent prevalence reported among white adults. Rosacea occurs in nonwhite populations, but prevalence data is li...
Read MoreDistinct Approaches to Perioperative Management of Anticoagulation and Antiplatelet Therapy among Providers Performing Cutaneous Surgery
July 2022 | Volume 21 | Issue 7 | Original Article | 766 | Copyright © July 2022
Background: Despite increasing cross-collaboration between providers who perform cutaneous surgery, a disparity still exists in the current practices regarding perioperative managemen...
Read MoreSafety and Efficacy of TGF-β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
May 2022 | Volume 21 | Issue 5 | Original Article | 472 | Copyright © May 2022
This single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-Read More
A Rare Case of Empedobacter Brevis Cutaneous Infection Treated Successfully With Oral Sarecycline
February 2022 | Volume 21 | Issue 2 | Case Reports | 201 | Copyright © February 2022
Empedobacter brevis (E. brevis) is a gram-negative, nonmotile, aerobic bacteria that is part of the Flavobacteriaceae family. It is mostly found in water sources, plants, soils, and more recently, hos...
Read MoreThe Potential for Teledermatology in Managing and Diagnosing Patients With Cutaneous Lymphomas
November 2020 | Volume 19 | Issue 11 | Features | 1125 | Copyright © November 2020
Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations
September 2020 | Volume 19 | Issue 9 | Case Reports | 894 | Copyright © September 2020
Epidermal growth factor (EGFR)-inhibitors have emerged as the primary therapy in advanced solid tumor malignancies because of improvement in survival with overall favorable side effect profile. Howeve...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
